Drug Prices

The price of prescription drugs has skyrocketed over the past several years. These price increases are extremely troublesome throughout the health care system.

Unchecked drug price increases are not sustainable, and are a serious economic threat to the patients and communities we serve. They not only threaten patient access to drug therapies, but challenge providers’ abilities to provide the highest quality of care.

Did you know?

  • In 2015, total spending on prescription drugs surpassed $457 billion
  • Spending on drugs rose 8.5% in 2015
  • The cost of some drugs jumped as much as 3,600% over two years

Hospitals bear a heavy financial burden when the cost of drugs increases. They are not only major purchasers of drugs, but patients often end up in the hospital when they cannot afford to take their medications as prescribed.

To that end, the American Hospital Association is proud to be a member of the Campaign for Sustainable Rx Pricing -– a diverse coalition of doctors, hospitals, pharmacists, employers, health plans, seniors, patients, consumers and others coming together to find common ground and solutions.

Moving forward, the AHA is committed to working for action on policies that foster transparency, competition and value while fostering innovation.

Read on to learn more about the impact of high drug pricing on patients and hospitals.

Related Resources

AHA Center for Health Innovation Market Scan
Intermountain Healthcare has agreed to sell its Intalere group purchasing organization (formerly Amerinet) to Vizient, a GPO that also provides data analytics…
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Fact Sheets
Public
The Issue: Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at…
Special Bulletin
Public
Summary of President Trump’s executive order to address drug pricing via “most-favored-nation” pricing model.
Action Alert
Member
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana…
Letter/Comment
Public
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our…